Trieste, Italy

Roberto Marzari

This inventor holds 4 USPTO granted patents and 1 EPO patent. Top assignees: Adienne Srl, Adienne S.a., Quark Pharmaceuticals, Inc.. Active years: 2011-2015.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Roberto Marzari. Retrieved from https://idiyas.com/inventor/roberto-marzari

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank


Average Co-Inventor Count = 2.2

ph-index = 3

Forward Citations = 41(Granted Patents)


Location History:

  • Munrupino, IT (2011)
  • Trieste, IT (2011 - 2015)

Company Filing History:


Years Active: 2011-2015

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Roberto Marzari: Inventor in Complement-Targeted Therapeutics

Introduction

Roberto Marzari is an inventor associated with Trieste, Italy. His patent work includes recombinant antibodies designed to target the C5 component of the activated complement system. He is associated with 4 patents.

Latest Patents

Two of Marzari’s latest patent titles are “Anti-C5 Alpha Antibodies” and “Methods of Treating a Disease with Anti-C5 Alpha Antibodies.” Both describe human-origin recombinant antibodies that bind the C5 component and inhibit the conversion of its alpha chain into C5a and C5b.

The inventions also cover nucleotide sequences encoding these antibodies and their potential therapeutic use. The described applications include treating diseases involving tissue damage caused by uncontrolled activation of the complement system.

Career Highlights

Marzari’s professional affiliations include Adienne Srl and Quark Pharmaceuticals, Inc. His patent work reflects a focus on antibody-based approaches to complement-related disease.

Collaborations

His listed coworkers include Francesco Tedesco and Daniele Sblattero. Their shared professional context includes research and development related to biotechnology and therapeutic inventions.

Conclusion

Roberto Marzari’s patent portfolio highlights antibody and nucleotide-based approaches aimed at controlling complement activation and addressing related tissue damage.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…